MRI示踪的纳米酶用于级联反应增强的免疫治疗

隋美菊, 张磊, 王瑞芳, 骆盈盈, 李莎, 丘茂松, 徐秋怡, 陈代钦, 陈世桢, 周欣

MRI-traceable Nanoenzyme for Cascade Catalysis-enhanced Immunotherapy

SUI Meiju, ZHANG Lei, WANG Ruifang, LUO Yingying, LI Sha, QIU Maosong, XU Qiuyi, CHEN Daiqin, CHEN Shizhen, ZHOU Xin

图7 光热增强MH NPs介导的抗肿瘤催化免疫治疗联合αPD-L1对4T1移植瘤的治疗效果. (a)光热增强MH NPs介导的抗肿瘤催化免疫治疗联合αPD-L1的治疗示意图；(b, e)接受不同治疗的4T1荷瘤小鼠原发（Primary）和远端（Distant）肿瘤的生长曲线；(c, f)接受不同治疗的4T1荷瘤小鼠原发和远端肿瘤的重量；(d, g)接受不同治疗的4T1荷瘤小鼠原发和远端肿瘤的照片；(h)接受不同治疗的4T1荷瘤小鼠原发肿瘤的H&E和TUNEL组织染色分析

Fig. 7 Photothermal-enhanced MH NPs-mediated anti-tumor catalytic immunotherapy synergized with αPD-L1 against 4T1 tumor xenografts. (a) Schematic illustration of the photothermal-enhanced MH NPs-meidated anti-tumor catalytic immunotherapy synergized with αPD-L1; (b, e) Primary and distant tumor growth curves of the 4T1 tumor-bearing mice with different treatments; (c, f) The weight of primary and distant tumors in 4T1 tumor-bearing mice with different treatments; (d, g) Photographs of primary and distant tumors in 4T1 tumor-bearing mice with different treatments; (h) H&E and TUNEL staining histological analysis of primary tumor sections from 4T1 tumor-bearing mice with different treatments